Bracanat 150 (Olaparib 150mg)

The most effective generic poly polymerase inhibitor for treating germline BRCA mutated (gBRCAm) advanced ovarian cancer, following three or more rounds of chemotherapy, is Bracanat 150 (Olaparib 150mg). Additionally, it is also the first PARP inhibitor to be used for gBRCAm metastatic breast cancer.

Ovarian cancer:

1. Olaparib 100mg is approved as a maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy.

2. Olaparib 100mg is also indicated for the treatment of adult patients with advanced ovarian cancer, who have deleterious or suspected deleterious germline BRCA mutations (gBRCAm) and have received three or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic.

Breast cancer: Olaparib 100mg is approved for the treatment of patients with metastatic breast cancer, who have deleterious or suspected deleterious gBRCAm and negative human epidermal growth factor receptor 2 (HER2) status. Patients should have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and those with hormone receptor (HR)-positive breast cancer should have received prior endocrine therapy or be deemed unsuitable for such therapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic.

Olaparib dose

1. The recommended tablet dose for this medication is 300mg to be taken orally twice daily, with or without food.

2. In the event of adverse reactions, it is advisable to consider interrupting or reducing the dose.

3. In cases of moderate renal impairment (with a creatinine clearance of 31-50 mL/min), the dose should be reduced to 200mg taken orally twice daily.

Olaparib 150 mg price in India

The price of Olaparib 50mg is approximately 15099 USD for a pack of 120 tablets. However, the cost of generic Olaparib 50mg is only 8% of the brand name version when purchased from an online pharmacy in India.

Olaparib Side Effects:

Olaparib has the potential to cause severe side effects, which include:

1. Bone marrow problems, such as Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), which have been observed in some patients with ovarian or breast cancer who received prior chemotherapy, radiotherapy or specific medications for their cancer. In such cases, MDS or AML may prove fatal. If you develop MDS or AML during Olaparib treatment, your healthcare provider will halt the medication.

Symptoms of low blood cell counts are common during Olaparib treatment, and may indicate serious bone marrow problems, including MDS or AML. These symptoms may include:

• Fatigue
• Weakness
• Weight loss
• Frequent infections
• Fever
• Blood in urine or stool
• Shortness of breath
• Easy bruising or bleeding

Your healthcare provider will monitor your blood cell counts regularly, before and during Olaparib treatment. If low blood cell counts persist for an extended period, they may recommend stopping Olaparib until your blood cell counts improve.

2. Lung problems, such as pneumonitis, which can manifest as symptoms such as cough, wheezing, fever, and shortness of breath. Inform your healthcare provider of any new or worsening lung-related symptoms, and they may conduct a chest x-ray. If pneumonitis occurs, your healthcare provider may temporarily or permanently discontinue Olaparib treatment. Pneumonitis can be fatal.

Olaparib PI

For more Prescribing information，please ask for “FDA Prescribing Information” from our customer support.